Schilbach Katharina, Olsson Daniel S, Boguszewski Margaret C S, Bidlingmaier Martin, Johannsson Gudmundur, Jørgensen Jens-Otto Lunde
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.
Department of Internal medicine and clinical nutrition, Sahlgrenska academy, University of Gothenburg, Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Growth Horm IGF Res. 2018 Jun;40:1-8. doi: 10.1016/j.ghir.2018.03.005. Epub 2018 Mar 20.
Growth hormone (GH) and IGF-I levels in serum are used as biomarkers in the diagnosis and management of GH-related disorders but have not been subject to structured validation. Auxological parameters in children and changes in body composition in adults, as well as metabolic parameters and patient related outcomes are used as clinical and surrogate endpoints. New treatment options, such as long acting GH and GH antagonists, require reevaluation of the currently used biochemical biomarkers. This article will review biomarkers, surrogate endpoints and clinical endpoints related to GH treatment in children and adults as well as in acromegaly.
血清中的生长激素（GH）和胰岛素样生长因子-I（IGF-I）水平被用作生长激素相关疾病诊断和管理的生物标志物，但尚未经过系统验证。儿童的体格测量参数、成人身体成分的变化以及代谢参数和患者相关结局被用作临床和替代终点。新的治疗选择，如长效生长激素和生长激素拮抗剂，需要对目前使用的生化生物标志物进行重新评估。本文将综述与儿童、成人以及肢端肥大症患者生长激素治疗相关的生物标志物、替代终点和临床终点。
